<DOC>
	<DOCNO>NCT00485394</DOCNO>
	<brief_summary>The purpose trial compare ability two dose OT-551 ophthalmic solution drug-free solution safely effectively treat geographic atrophy associate age-related macular degeneration .</brief_summary>
	<brief_title>The OMEGA Study : Use Eye Drops Treat Geographic Atrophy Associated With Age-Related Macular Degeneration ( Dry AMD )</brief_title>
	<detailed_description>Age-related macular degeneration ( AMD ) result severe , irreversible central vision loss lead cause blindness individual older 50 year western world . The vast majority AMD patient 'dry ' ( non-exudative ) form characterize presence drusen atrophic change retinal pigment epithelium ( RPE ) . Dry AMD may remain static progress slowly produce area geographic atrophy ( GA ) , advance late-stage form dry AMD . GA severe vision-threatening lesion macula may impair visual function , impact daily life activity , result blindness . Currently , approve treatment dry AMD GA. Pre-clinical result show OT-551 may protect RPE cell photoreceptors oxidative damage block angiogenesis stimulate VEGF growth factor , therefore therapeutic candidate treat GA .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>clinical diagnosis GA one eye ; nonchildbearing potential GA secondary condition AMD study eye ; BCVA 20/200 bad nonstudy eye ; history current choroidal neovascularization either eye , need study eye antiangiogenic therapy ; ocular condition study eye would progress course study could affect central vision ocular condition may confound factor study ; need wear contact lens study eye study ; confound ocular surgery study eye ; concomitant treatment systemic ocular medication know toxic lens , retina , optic nerve ;</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>AMD</keyword>
	<keyword>age-related macular degeneration</keyword>
	<keyword>geographic atrophy</keyword>
	<keyword>GA</keyword>
</DOC>